Jeena Sikho Lifecare Limited has informed stock exchanges about the publication of nine academic case studies and case reports in various medical journals on January 7, 2026. The publications demonstrate the company's ongoing commitment to advancing Ayurvedic research and promoting evidence-based clinical practices.

Academic Publications Overview

The company disclosed that these academic publications have been authored by medical professionals associated with Jeena Sikho Lifecare Limited, including the Managing Director, senior consultants, and Ayurvedic experts. The studies focus on various medical conditions and their treatment through Ayurvedic approaches.

Published Studies and Research Areas

The nine publications cover a diverse range of medical conditions treated through Ayurvedic medicine:

Research Scope and Medical Conditions

The published studies encompass treatment approaches for several significant health conditions:

• Metabolic Disorders: Studies on diabetes mellitus (Madhumeha) and dyslipidemia management
• Endocrine Conditions: Research on hypothyroidism treatment through Ayurvedic methods
• Oncology Applications: Symptomatic relief approaches for recurrent breast cancer lesions
• Kidney Disorders: Multiple studies on chronic kidney disease (Vrikka Vikara) management
• Gastrointestinal Issues: Clinical case study on duodenal ulcer treatment
• Neurological Conditions: Research on Vata Vyadhi management
• Cardiovascular Health: Comprehensive approach to coronary artery disease

Regulatory Compliance

The company made this disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The intimation was sent to both the National Stock Exchange of India Limited and BSE Limited on January 7, 2026, with complete details and links to all published studies provided for regulatory records.

Company Profile

Jeena Sikho Lifecare Limited operates over 120 Ayurveda clinics and hospitals, positioning itself as a provider of traditional Ayurvedic healthcare solutions. The company's registered office is located in Zirakpur, Punjab, with its corporate office in New Delhi.

Jeena Sikho Lifecare Limited has received the National Accreditation Board for Hospitals & Healthcare Providers (NABH) Certificate of Accreditation for its Sanganer Hospital, marking a significant milestone in the company's commitment to quality healthcare delivery. The company announced this development on January 1, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Accreditation Details

The NABH accreditation specifically covers Panchakarma services at the Sanganer Hospital located in Rajasthan. The certification demonstrates the facility's compliance with nationally recognized healthcare standards.

Significance of NABH Accreditation

The receipt of NABH accreditation represents adherence to nationally recognized standards across multiple critical areas of healthcare operations. This certification validates the hospital's commitment to quality healthcare delivery, patient safety protocols, and operational excellence. The accreditation process involves rigorous evaluation of healthcare facilities against established benchmarks.

Business Impact

The company has indicated that this development has occurred in the ordinary course of business. The NABH accreditation enhances the credibility and recognition of Jeena Sikho Lifecare Limited's healthcare services, particularly in the specialized area of Panchakarma treatments at its Rajasthan facility.

Regulatory Compliance

The announcement was made in compliance with regulatory disclosure requirements under SEBI regulations. Additional information regarding this development is available on the company's investor relations website at https://jeenasikho.com/investors , ensuring transparency for stakeholders and investors.